Syngo.via RT Image Suite

The syngo.via RT Image Suite SOMARIS/8 VB50 is presented as a software tool to advance radiation therapy planning by offering enhanced multi-modality image visualization, manipulation, and precise contouring of tumors and organs-at-risk. It employs digital image processing methods, notably an expanded deep learning-based algorithm for automated organ segmentation, aiming to increase the efficiency and accuracy of preparing diverse radiation treatments.

The syngo.via RT Image Suite, software version SOMARIS/8 VB50, is described in the document as an image analysis software intended for use in radiation therapy planning. Its core function is to enable medical professionals to view, manipulate, visualize (in 3D and 4D), and compare medical images from various modalities such as CT, PET, MRI, and CBCT. The software is designed to aid in the segmentation of tumors and organs-at-risk, the creation and modification of contours, and the management of points of interest like the isocenter, thereby supporting case preparation for treatments including Brachytherapy, Particle Therapy, and External Beam Radiation Therapy. It incorporates a range of digital image processing tools for these tasks, including capabilities for multi-modality image fusion, both rigid and deformable image registration, and the generation of simple geometric treatment plans, with the final results being exportable to dedicated Treatment Planning Systems. This version of the software, SOMARIS/8 VB50, introduces several modifications and enhancements compared to its predicate (SOMARIS/8 VB40), as detailed in the document. These include improvements in routine and advanced contouring functionalities, structure set management, and deformable alignment tools. A significant update highlighted is the transition of automatic contouring for the head/neck region from a previous atlas-based method to a deep learning algorithm; this deep learning approach, utilizing a Deep Image-to-Image Network, has also been extended for automated organ segmentation in additional anatomical regions like the thorax and pelvis. The document states that performance data, derived from software verification, validation, non-clinical testing, and a specific algorithm evaluation involving 112 subjects, demonstrated that the updated software performs as intended. This evaluation reportedly showed the segmentation algorithm to have non-inferior or superior accuracy (using the DICE coefficient against manual annotations) compared to the predicate version, with newly added organs achieving a 100% detection rate.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the performance of the deep learning-based automatic contouring for head/neck regions, as described in this document, compare to the previous atlas-based method in terms of accuracy, consistency, and processing time across diverse patient anatomies?; What specific anatomical landmarks are detailed in the documentation for the "Deep Image-to-Image Network" for organ detection, and how does the document address the robustness of this detection across variations in image quality or patient positioning?; Can the document provide more specifics on the validation dataset characteristics (e.g., patient demographics, pathology variety, scanner types) used to confirm the "non-inferior or superior performance" of the extended organ segmentation portfolio, particularly for the newly added thoracic and pelvic organs?; What quantitative improvements or user feedback metrics, if detailed in the supporting data, were observed with the simplified deformation visualization tool in deformable alignment, and how does the document suggest this impacts user workflow efficiency or interpretation accuracy?; Regarding the generation of a synthetic CT from MRI, what data does this document provide on its typical geometric accuracy and Hounsfield unit fidelity compared to an actual CT, and what are its validated clinical applications or limitations in treatment planning as per the performance data?